Shire to present new Adynovate data at WFH congress

Shire will be present new clinical data demonstrating the benefits of its haemophilia A therapy Adynovate at the International Congress of the World Federation of Hemophilia (WFH).

More than a dozen scientific updates on the company's broad portfolio of treatments for bleeding disorders will be showcased at the congress in Orlando, including Adynovate, its extended half-life recombinant factor VIII (FVIII) replacement therapy for haemophilia A.

One of these studies will demonstrate the safety and efficacy of the drug among previously-treated children with haemophilia A, while another analysis will assess its long-term safety performance.

Adynovate is built on a proven protein, Advate, and is designed to extend the time FVIII circulates in the body, offering dosing flexibility to help achieve personalised treatment goals.

Dr Leonard Valentino, global head of haematology medical affairs at Shire, said: "We are committed to reducing the burden of haemophilia A for patients of all ages worldwide and look forward to expanding availability of this treatment option."

The drug was developed by Baxalta and is now owned by Shire following the recent completion of its takeover of the company.